RENBIO

WIPO WIPO 2021

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark RENBIO was filed as Word mark on 04/29/2021 at the World Intellectual Property Organization.

Trademark Details Last update: November 15, 2022

Trademark form Word mark
File reference 1599800
Countries Australia Brazil Canada China em United Kingdom India Japan
Base trademark US No. 90309237, November 10, 2020
Application date April 29, 2021
Expiration date April 29, 2031

Trademark owner

30-02 48th Avenue
Long Island City NY 11101
US

Trademark representatives

Morgan, Lewis & Bockius LLP, One Federal Street US

goods and services

01 Biological products, namely, DNA circle, DNA primers, linear DNA and buffers for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals; biological products, namely, antibodies, multi-specific antibodies, antibody fragments, proteins, chimeric proteins, drug conjugates and enzymes, for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals
05 Chemical preparations for gene delivery pharmaceuticals for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for gene therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for gene therapy analysis; gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions; pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; biological preparations for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; nucleic acid sequences for medical purposes; pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals
10 Medical apparatus for the administration of biopharmaceuticals and vaccines, namely, drug delivery devices and systems; medical devices, namely, for electroporation mediated administration of drugs to humans and animals; delivery systems for administration of biopharmaceuticals and vaccines for the preventive or treatment of disease in humans and animals; handheld medical systems and devices using electroporation for the prevention or treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders in humans and animals; handheld clinical delivery systems and devices for the application of electrical fields in tissue, in particular muscle and skin, in conjunction with the administration of biopharmaceuticals
42 Medical and scientific research in the field of drug delivery devices; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines

Trademark history

Date Document number Area Entry
November 10, 2022 2022/46 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
October 5, 2022 2022/40 Gaz CA Rejection
August 2, 2022 2022/31 Gaz BR Rejection
May 26, 2022 2022/22 Gaz JP Rejection
January 18, 2022 2022/7 Gaz AU RAW: Rule 18ter(2)(ii) GP following a provisional refusal
December 2, 2021 2021/52 Gaz CN Rejection
December 1, 2021 2021/48 Gaz GB Rejection
November 23, 2021 2021/47 Gaz EM Rejection
July 14, 2021 2021/29 Gaz AU Rejection
July 13, 2021 2021/29 Gaz IN Rejection
April 29, 2021 2021/24 Gaz US Registration

ID: 141599800